IFN-α6 Inhibitors

IFN-α6 inhibitors, as classified in this context, are primarily JAK inhibitors. These compounds are designed to target the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, which plays a pivotal role in the action of interferons, including IFN-α6. The inhibitors listed above vary in their specificity for different JAK enzymes. Some, like Ruxolitinib and Tofacitinib, are more broad-spectrum JAK inhibitors, while others, such as Oclacitinib and Filgotinib, are more selective for specific JAK enzymes.

These inhibitors operate by binding to the ATP-binding site of the JAK enzymes, preventing their phosphorylation and subsequent activation. This inhibition results in reduced phosphorylation and activation of STAT proteins, which are critical for transmitting signals from the cell surface to the nucleus. By disrupting this pathway, these inhibitors can modulate the immune response mediated by interferons, including IFN-α6.